
Lifestyle interventions are foundational to hypertension prevention and treatment. We review recent evidence for weight management, dietary patterns, sodium and potassium intake, physical activity, stress reduction, alcohol reduction, and avoidance of blood pressure-raising substances, with emphasis on implementation and contemporary guidelines. Recent trials extend Dietary Approaches to Stop Hypertension (DASH) benefits to grocery delivery in populations facing barriers to food access, while potassium-enriched salt-substitution studies support cardiovascular benefit but require attention to hyperkalemia risk. Alcohol reduction lowers blood pressure most among individuals with higher baseline intake or blood pressure, and avoidance of other pressor substances remains important. Evidence for time-restricted eating and stress-reduction strategies is uncertain. Lifestyle modification is recommended for all adults with elevated blood pressure or hypertension, but sustained adherence and equitable access are major barriers. Future research should prioritize scalable, durable, culturally responsive strategies and outcomes beyond short-term blood pressure change.
Chronic kidney disease (CKD) has almost never been counted as an important incident endpoint in randomized clinical trials (RCTs) in the prevention of complications and outcomes in essential hypertension but rather included in broader safety assessments. Although target systolic blood pressure (SBP) < 130 and even < 120 mmHg is recommended by some guidelines, it is unclear whether such aggressive treatment has a favorable effect on hypertension-related decline of CKD. During the past two decades several RCTs have been performed with patients randomized to more aggressive SBP target vs. SBP target closer to standard treatment. Several large RCTs have targeted and/or otherwise achieved SBP as low as 120 mmHg or maybe even lower in fractions of middle-aged and older high risk essential hypertensive people with major worsening of kidney function. However, other RCTs showed neutral effects or even reduction in kidney endpoints with achieved SBP below 130 mmHg and possible benefit in preventing cardiovascular outcomes though inclusion of soft endpoints in some trials diluted the cardiovascular message. Intensive BP lowering is associated with greater declines in kidney function in all major RCTs investigating target SBP < 120 mmHg. The long-term clinical significance of these changes must be interpreted alongside possible cardiovascular risks. Hence, one should aim at a SBP target < 130 mmHg in middle-aged and older hypertensive patients if the treatment is otherwise well tolerated. The benefits of low SBP targets in patients who develop CKD should be reassessed in the context of new available treatments providing kidney protection such as SGLT2-inhibitors, aldosterone antagonists and GLP1-agonists.
This review examines the epidemiology, mechanisms, and management of hypertension in patients with cancer, emphasizing treatment-related hypertension, autonomic dysfunction, blood pressure lability, and evolving blood pressure targets in cardio-oncology. Among cancer survivors both during and after their cancer treatment, hypertension is highly prevalent and is associated with increased cardiovascular morbidity and mortality. Vascular endothelial growth factor (VEGF) inhibitors are one of the most common causes of cancer treatment-induced hypertension, although other cancer treatments also contribute. Emerging evidence highlights the coexistence of orthostatic hypotension and hypertension, likely related to autonomic dysfunction, arterial stiffening, baroreflex impairment, and endothelial dysfunction related to cancer and its treatment. Medical management, intensive blood pressure control, and cardio-oncology rehabilitation may improve blood pressure control while mitigating adverse outcomes. Current hypertension management in cancer survivors largely follows general population guidelines despite the unique pathophysiology of cancer and its therapies. Future research should establish cancer-specific blood pressure targets, optimize antihypertensive strategies, and further investigate management of blood pressure lability, autonomic dysfunction, and cardio-oncology rehabilitation.
Adrenergic C1 neurons in the rostral ventrolateral medulla (RVLMC1) have long been recognized for their role in regulating sympathetic activity and arterial blood pressure (BP). However, novel approaches such as genetic targeting, optogenetics, fiber photometry, among others, allowed us to study the biology of these neurons in deeper detail and in non-anesthetized preparations, unraveling previously underappreciated or unrecognized functions. Here we will discuss recent studies that explored the function of RVLMC1 neurons for the sympathetic regulation of BP and also the emergent roles of these cells for other processes involved in systemic physiological regulation. Using selective methods of manipulation and recording of neuronal activity in conscious animals, it was demonstrated that RVLMC1 neurons play a critical role in BP stability across multiple behaviors, including sleep-wake state and postural changes. Besides cardiovascular control, recent evidence shows that these neurons play a critical role in different homeostatic functions such as thermoregulation, immune response, glycemia and in complex behaviors such as anxiety. RVLMC1 neurons are a key hub that integrates interoceptive signals from peripheral systems to regulate BP and other basic physiological functions. Along with their role in cardiovascular regulation, these emergent roles of RVLMC1 neurons may also need to be considered when explaining the complex and multifactorial pathophysiology of cardiometabolic diseases associated with hypertension.
Primary aldosteronism (PA) is common, underdiagnosed, and associated with excess cardiorenal risk. We review recent changes in screening, diagnosis, treatment, and implementation. Contemporary guidelines have broadened screening and reduced barriers to aldosterone-to-renin ratio testing through medication-tolerant, assay-aware interpretation. Confirmatory aldosterone suppression testing is increasingly de-emphasized, with selective use or omission in high-probability patients when results are unlikely to change management. Adrenal vein sampling remains standard for most surgical candidates, while molecular imaging is emerging as a noninvasive alternative. Adrenalectomy is preferred for lateralizing disease; mineralocorticoid receptor antagonists remain first-line therapy for bilateral or nonoperative disease, with renin response increasingly used to assess dosing adequacy. Finerenone and aldosterone synthase inhibitors are potential emerging options. PA care is shifting from a rigid multistep workup toward earlier detection and treatment-directed evaluation. Future work should define scalable screening pathways and compare outcomes of emerging diagnostic and therapeutic strategies.